MichaÅ, Tendera

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2783816/publications.pdf

Version: 2024-02-01

134 papers	70,720 citations	18482 62 h-index	11939 134 g-index
142 all docs	142 docs citations	142 times ranked	49811 citing authors

#	Article	IF	Citations
1	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	2.2	5,233
2	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	2.2	5,034
3	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
4	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	2.2	3,915
5	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
6	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	2.2	3,144
7	Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine, 2001, 344, 1651-1658.	27.0	2,909
8	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	2.2	2,767
9	Third Universal Definition of Myocardial Infarction. Circulation, 2012, 126, 2020-2035.	1.6	2,722
10	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2010, 31, 2501-2555.	2.2	2,649
11	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace, 2012, 14, 1385-1413.	1.7	2,319
12	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.1	2,307
13	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	2.2	2,305
14	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
15	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	2.2	2,176
16	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	1.4	2,164
17	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008â€¡. European Journal of Heart Failure, 2008, 10, 933-989.	7.1	1,893
18	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.2	1,758

#	Article	IF	Citations
19	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2006, 28, 1462-1536.	2.2	1,617
20	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2851-2906.	2.2	1,394
21	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 807-816.	13.7	934
22	Resting Heart Rate in Cardiovascular Disease. Journal of the American College of Cardiology, 2007, 50, 823-830.	2.8	867
23	Mobilization of Bone Marrow-Derived Oct-4+ SSEA-4+ Very Small Embryonic-Like Stem Cells in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2009, 53, 1-9.	2.8	835
24	Editor's Choice â€“ 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 2018, 55, 305-368.	1.5	734
25	Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet, The, 2008, 372, 817-821.	13.7	694
26	Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 392, 1036-1046.	13.7	619
27	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2008, 358, 2205-2217.	27.0	596
28	European Society of Cardiology: Cardiovascular Disease Statistics 2017. European Heart Journal, 2018, 39, 508-579.	2.2	595
29	Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. European Heart Journal, 2012, 33, 2831-2840.	2.2	560
30	Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. European Heart Journal, 2005, 26, 2529-2536.	2.2	502
31	Expert consensus document on ?-adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of Cardiology. European Heart Journal, 2004, 25, 1341-1362.	2.2	465
32	Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine, 2013, 368, 1210-1219.	27.0	462
33	Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. European Heart Journal, 2009, 30, 1313-1321.	2.2	427
34	Cardiopoietic Stem Cell Therapy in Heart Failure. Journal of the American College of Cardiology, 2013, 61, 2329-2338.	2.8	427
35	Mobilization of CD34/CXCR4 ⁺ , CD34/CD117 ⁺ , c-met ⁺ Stem Cells, and Mononuclear Cells Expressing Early Cardiac, Muscle, and Endothelial Markers Into Peripheral Blood in Patients With Acute Myocardial Infarction. Circulation, 2004, 110, 3213-3220.	1.6	423
36	Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. New England Journal of Medicine, 2014, 371, 1091-1099.	27.0	399

#	Article	IF	Citations
37	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet, The, 2016, 388, 2142-2152.	13.7	357
38	Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in Patients With Acute Myocardial Infarction Based on Individual Patient Data. Circulation Research, 2015, 116, 1346-1360.	4.5	270
39	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.	1.4	261
40	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 877-886.	11.4	245
41	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2Â°P-TIMI 50 trial. Lancet, The, 2012, 380, 1317-1324.	13.7	202
42	Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. European Heart Journal, 2009, 30, 2337-2345.	2.2	192
43	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, The, 2017, 389, 1799-1808.	13.7	174
44	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD â€“ Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.	2.0	173
45	The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. European Heart Journal, 2006, 27, 1338-1340.	2.2	155
46	2010 Focused Update of ESC Guidelines on device therapy in heart failure. European Journal of Heart Failure, 2010, 12, 1143-1153.	7.1	152
47	Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. European Heart Journal, 2017, 38, ehw543.	2.2	148
48	Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. European Heart Journal, 2014, 35, 989-998.	2.2	123
49	Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease. JAMA Internal Medicine, 2014, 174, 1651.	5.1	118
50	EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal, 2016, 37, 1296.1-1303.	2.2	112
51	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	2.2	94
52	Mobilization of CD34+, CD117+, CXCR4+, c-met+ stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. European Heart Journal, 2006, 27, 283-289.	2.2	92
53	Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, 1853-1859.	2.8	89
54	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal, 2013, 34, 2263-2270.	2.2	85

#	Article	IF	Citations
55	Congestive Heart Failure Cardiopoietic Regenerative Therapy (<scp>CHART</scp>â€1) trial design. European Journal of Heart Failure, 2016, 18, 160-168.	7.1	77
56	Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 2015, 131, 1047-1053.	1.6	73
57	Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. American Heart Journal, 2013, 165, 509-514.e7.	2.7	72
58	Paracrine Proangiopoietic Effects of Human Umbilical Cord Blood-Derived Purified CD133⁺Cellsâ€"Implications for Stem Cell Therapies in Regenerative Medicine. Stem Cells and Development, 2013, 22, 422-430.	2.1	72
59	Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease. PLoS ONE, 2012, 7, e36284.	2.5	70
60	Î²-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. European Heart Journal, 2019, 40, 1399-1407.	2.2	66
61	Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease. International Journal of Cardiology, 2013, 167, 2938-2943.	1.7	64
62	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. American Heart Journal, 2021, 231, 121-127.	2.7	60
63	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. European Heart Journal, 2016, 37, 164-173.	2.2	56
64	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. European Heart Journal, 2020, 41, 347-356.	2.2	55
65	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. American Heart Journal, 2014, 168, 23-29.e2.	2.7	50
66	Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry. European Journal of Preventive Cardiology, 2015, 22, 1056-1065.	1.8	50
67	The effect of intracoronary infusion of bone marrowâ€derived mononuclear cells on allâ€cause mortality in acute myocardial infarction: rationale and design of the <scp>BAMI</scp> trial. European Journal of Heart Failure, 2017, 19, 1545-1550.	7.1	45
68	Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 396, 830-838.	13.7	44
69	Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension. Hypertension, 2018, 71, 168-176.	2.7	41
70	Rationale, design, and baseline characteristics of the <scp>CLARIFY</scp> registry of outpatients with stable coronary artery disease. Clinical Cardiology, 2017, 40, 797-806.	1.8	40
71	The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clinical Research in Cardiology, 2012, 101, 585-591.	3.3	38
72	Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease. American Journal of Medicine, 2017, 130, 720-730.	1.5	38

#	Article	IF	Citations
73	Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. European Heart Journal, 2015, 36, ehv451.	2.2	37
74	Effects of Transendocardial Delivery of Bone Marrowâ€"Derived CD133 ⁺ Cells on Left Ventricle Perfusion and Function in Patients With Refractory Angina. Circulation Research, 2017, 120, 670-680.	4.5	35
75	Safety of Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction (from the BEAUTIFUL Holter Substudy). American Journal of Cardiology, 2011, 107, 805-811.	1.6	34
76	Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2019, 73, 1362-1364.	2.8	34
77	Mobilization of CD34+CXCR4+ Stem/Progenitor Cells and the Parameters of Left Ventricular Function and Remodeling in 1-Year Follow-up of Patients with Acute Myocardial Infarction. Mediators of Inflammation, 2012, 2012, 1-11.	3.0	33
78	Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. International Journal of Cardiology, 2014, 176, 119-124.	1.7	30
79	Efficacy of I_f Inhibition with Ivabradine in Different Subpopulations with Stable Angina Pectoris. Cardiology, 2009, 114, 116-125.	1.4	29
80	Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. American Heart Journal, 2013, 166, 654-661.e6.	2.7	27
81	Artificial Intelligence Can Improve Patient Management at the Time of a Pandemic: The Role of Voice Technology. Journal of Medical Internet Research, 2021, 23, e22959.	4.3	27
82	Living alone and cardiovascular disease outcomes. Heart, 2019, 105, 1087-1095.	2.9	26
83	International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. Circulation, 2021, 144, 512-523.	1.6	25
84	Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction. American Journal of Medicine, 2015, 128, 1102-1108.e6.	1.5	24
85	Cardiopoietic stem cell therapy in ischaemic heart failure: longâ€term clinical outcomes. ESC Heart Failure, 2020, 7, 3345-3354.	3.1	23
86	Impact of Chronic Kidney Disease on Use of Evidence-Based Therapy in Stable Coronary Artery Disease: A Prospective Analysis of 22,272 Patients. PLoS ONE, 2014, 9, e102335.	2.5	21
87	Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. European Heart Journal, 2018, 39, 3855-3863.	2.2	21
88	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. European Journal of Preventive Cardiology, 2020, 27, 426-436.	1.8	21
89	Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease. European Journal of Preventive Cardiology, 2021, 28, 1460-1466.	1.8	21
90	Transcatheter paravalvular leak closure and hemolysis â€" a prospective registry. Archives of Medical Science, 2017, 3, 575-584.	0.9	20

#	Article	IF	Citations
91	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2Â°P - TIMI 50 Trial. Clinical Chemistry, 2017, 63, 307-315.	3.2	19
92	ESC EORP Cardiomyopathy Registry: realâ€life practice of genetic counselling and testing in adult cardiomyopathy patients. ESC Heart Failure, 2020, 7, 3013-3021.	3.1	19
93	ARISTOTLE RE-LYs on the ROCKET. Whatâ€™s new in stroke prevention in patients with atrial fibrillation?. Cardiology Journal, 2012, 19, 4-10.	1.2	19
94	Reply. Journal of the American College of Cardiology, 2013, 62, 2454-2456.	2.8	17
95	Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry. Journal of Clinical Medicine, 2020, 9, 4.	2.4	17
96	Questions and Answers on Diagnosis and Management of Patients withÂPeripheral Arterial Diseases: A Companion Document of the 2017 ESCÂGuidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 2018, 55, 457-464.	1.5	16
97	Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, e35-e41.	2.2	16
98	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. PLoS ONE, 2015, 10, e0125164.	2.5	15
99	Quality of Life With Ivabradine in Patients With Angina Pectoris. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 31-38.	2.2	15
100	Intravenous ivabradine for control of heart rate during coronary CT angiography: A randomized, double-blind, placebo-controlled trial. Journal of Cardiovascular Computed Tomography, 2015, 9, 286-294.	1.3	13
101	Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. European Journal of Preventive Cardiology, 2022, 28, 1795-1806.	1.8	13
102	A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2	12
103	Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 186-193.	1.0	12
104	Causes of hospitalisation and prognosis in patients with cardiovascular diseases â€“ secular trends 2006-2014. SILesian CARDiovascular (SILCARD) database covering a population of 4.6 million subjects. Polish Archives of Internal Medicine, 2016, 126, 754-762.	0.4	12
105	Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. ESC Heart Failure, 2020, 7, 3601-3609.	3.1	11
106	Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry. European Heart Journal Cardiovascular Imaging, 2021, 22, 781-789.	1.2	10
107	Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective <scp>CLARIFY</scp> registry. European Journal of Heart Failure, 2020, 22, 804-812.	7.1	9
108	Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution?. Postepy W Kardiologii Interwencyjnej, 2013, 3, 234-240.	0.2	8

#	Article	IF	Citations
109	Long-term follow-up of renal arteries after radio-frequency catheter-based denervation using optical coherence tomography and angiography. International Journal of Cardiovascular Imaging, 2016, 32, 855-862.	1.5	8
110	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2Â°P-TIMI 50 trial. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 164-172.	1.0	8
111	Exercise-induced mobilisation of endothelial progenitor cells in patients with premature coronary heart disease. Kardiologia Polska, 2015, 73, 411-418.	0.6	8
112	Differences in presentation and management of Stable Angina from East to West in Europe: A comparison between Poland and the UK. International Journal of Cardiology, 2008, 125, 311-318.	1.7	5
113	How to measure the effects of the intracoronary stem cell therapy?. European Journal of Echocardiography, 2010, 11, 438-439.	2.3	5
114	Optical Coherence Tomography of De Novo Lesions and In-Stent Restenosis in Coronary Saphenous Vein Grafts (OCTOPUS Study). Circulation Journal, 2016, 80, 1804-1811.	1.6	5
115	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal, 2018, 199, 170-175.	2.7	5
116	Effects of trans-endocardial delivery of bone marrow-derived CD133+ cells on angina and quality of life in patients with refractory angina: A sub-analysis of the REGENT-VSEL trial. Cardiology Journal, 2018, 25, 521-529.	1.2	5
117	Association between socioeconomic status and cardiovascular risk. Kardiologia Polska, 2016, 74, 179-184.	0.6	5
118	Impact of anaemia on long-term outcomes in patients treated with first- and second-generation drug-eluting stents; Katowice-Zabrze Registry. Kardiologia Polska, 2016, 74, 561-569.	0.6	5
119	How can the European Society of Cardiology ensure compliance with ethical standards?. European Heart Journal, 2016, 37, 741-744.	2.2	4
120	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 134-142.	4.0	3
121	Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 287-294.	4.0	3
122	Prevalence, Incidence and Prognostic Implications of Left Bundle Branch Block in Patients with Chronic Coronary Syndromes (From the CLARIFY Registry). American Journal of Cardiology, 2021, 150, 40-46.	1.6	3
123	Use of risk scores to identify lower and higher risk subsets among COMPASSâ€eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry. Clinical Cardiology, 2021, 44, 58-65.	1.8	2
124	Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus non-cardiologists: the international prospective CLARIFY registry. Polish Archives of Internal Medicine, 2017, 127, 107-114.	0.4	2
125	Management strategies and 5-year outcomes in Polish patients with stable coronary artery disease in the CLARIFY registry versus other European countries. Polish Archives of Internal Medicine, 2019, 129, 327-334.	0.4	2
126	Primary PCI with endothelial progenitor cell-capture stent in patient with skull base fracture and aspirin allergy. Kardiologia Polska, 2013, 71, 210-210.	0.6	1

#	Article	IF	Citations
127	Traditional, forgotten and new left ventricular systolic function parameters on a 64-row multidetector cardiac computed tomography: A reproducibility study. Cardiology Journal, 2013, 20, 385-393.	1.2	1
128	Correlation between electromechanical parameters (NOGA XP) and changes of myocardial ischemia in patients with refractory angina. Postepy W Kardiologii Interwencyjnej, 2021, 17, 281-289.	0.2	1
129	Stroke prevention in patients with atrial fibrillation - anticoagulation strategy 2012. Cor Et Vasa, 2013, 55, e95-e100.	0.1	0
130	The role of imaging in coronary artery disease - What do the ESC guidelines say. Cor Et Vasa, 2015, 57, e405-e407.	0.1	0
131	Clinical Evidence That Oct-4+ ssea-4+ Very Small Embryonic Like Stem Cells (VSEL) Are Mobilized into Peripheral Blood in Patients with Acute Myocardial Infarction (AMI): A Novel Prognostic Indicator. Blood, 2008, 112, 2894-2894.	1.4	0
132	Cell Therapies in Cardiology. Pancreatic Islet Biology, 2014, , 79-93.	0.3	0
133	A single-centre, randomised study on platelet reactivity after abrupt or gradual discontinuation of long-term clopidogrel therapy in patients after percutaneous coronary intervention. Kardiologia Polska, 2016, 74, 634-643.	0.6	0
134	Cardiovascular risk of chronic coronary syndrome patients according to vascular phenotype, diabetes, and smoking. European Journal of Preventive Cardiology, 2020, , .	1.8	0